vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and RLJ Lodging Trust (RLJ). Click either name above to swap in a different company.
RLJ Lodging Trust is the larger business by last-quarter revenue ($340.0M vs $177.4M, roughly 1.9× Pacira BioSciences, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -1.9%, a 3.5% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs 3.6%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -4.1%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
The RLJ Companies is an American asset management firm owned by entrepreneur Robert Louis Johnson. After selling Black Entertainment Television in 2001, Johnson's first company, he created RLJ Companies in Bethesda, Maryland. The company's network includes hotel real estate investment, private equity, financial services, asset management, insurance services, car dealerships, sports and entertainment, and video lottery terminal (VLT) gaming. The company is headquartered in Bethesda and has add...
PCRX vs RLJ — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $340.0M |
| Net Profit | $2.9M | $-6.4M |
| Gross Margin | — | — |
| Operating Margin | 3.9% | 8.2% |
| Net Margin | 1.6% | -1.9% |
| Revenue YoY | 5.0% | 3.6% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.07 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | $340.0M | ||
| Q4 25 | $196.9M | $328.6M | ||
| Q3 25 | $179.5M | $330.0M | ||
| Q2 25 | $181.1M | $363.1M | ||
| Q1 25 | $168.9M | $328.1M | ||
| Q4 24 | $187.3M | $330.0M | ||
| Q3 24 | $168.6M | $345.7M | ||
| Q2 24 | $178.0M | $369.3M |
| Q1 26 | $2.9M | $-6.4M | ||
| Q4 25 | — | $430.0K | ||
| Q3 25 | $5.4M | $-3.7M | ||
| Q2 25 | $-4.8M | $28.5M | ||
| Q1 25 | $4.8M | $3.4M | ||
| Q4 24 | — | $5.4M | ||
| Q3 24 | $-143.5M | $20.6M | ||
| Q2 24 | $18.9M | $37.1M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — |
| Q1 26 | 3.9% | 8.2% | ||
| Q4 25 | 1.2% | 0.2% | ||
| Q3 25 | 3.5% | -1.0% | ||
| Q2 25 | 4.7% | 8.0% | ||
| Q1 25 | 1.2% | 1.1% | ||
| Q4 24 | 13.2% | 1.8% | ||
| Q3 24 | -82.8% | 6.1% | ||
| Q2 24 | 15.9% | 10.2% |
| Q1 26 | 1.6% | -1.9% | ||
| Q4 25 | — | 0.1% | ||
| Q3 25 | 3.0% | -1.1% | ||
| Q2 25 | -2.7% | 7.8% | ||
| Q1 25 | 2.8% | 1.0% | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | -85.1% | 6.0% | ||
| Q2 24 | 10.6% | 10.0% |
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $-0.05 | ||
| Q3 25 | $0.12 | $-0.07 | ||
| Q2 25 | $-0.11 | $0.15 | ||
| Q1 25 | $0.10 | $-0.02 | ||
| Q4 24 | $0.38 | $-0.01 | ||
| Q3 24 | $-3.11 | $0.09 | ||
| Q2 24 | $0.39 | $0.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $353.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $653.9M | $2.1B |
| Total Assets | $1.2B | $4.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | $353.1M | ||
| Q4 25 | $238.4M | $410.2M | ||
| Q3 25 | $246.3M | $374.8M | ||
| Q2 25 | $445.9M | $373.9M | ||
| Q1 25 | $493.6M | $347.5M | ||
| Q4 24 | $484.6M | $409.8M | ||
| Q3 24 | $453.8M | $385.4M | ||
| Q2 24 | $404.2M | $371.1M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | $2.2B | ||
| Q3 25 | $376.7M | $2.2B | ||
| Q2 25 | $580.5M | $2.2B | ||
| Q1 25 | $583.4M | $2.2B | ||
| Q4 24 | $585.3M | $2.2B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B |
| Q1 26 | $653.9M | $2.1B | ||
| Q4 25 | $693.1M | $2.2B | ||
| Q3 25 | $727.2M | $2.2B | ||
| Q2 25 | $757.8M | $2.2B | ||
| Q1 25 | $798.5M | $2.2B | ||
| Q4 24 | $778.3M | $2.3B | ||
| Q3 24 | $749.6M | $2.3B | ||
| Q2 24 | $879.3M | $2.3B |
| Q1 26 | $1.2B | $4.7B | ||
| Q4 25 | $1.3B | $4.7B | ||
| Q3 25 | $1.3B | $4.8B | ||
| Q2 25 | $1.5B | $4.8B | ||
| Q1 25 | $1.6B | $4.8B | ||
| Q4 24 | $1.6B | $4.9B | ||
| Q3 24 | $1.5B | $4.9B | ||
| Q2 24 | $1.6B | $4.9B |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | 1.01× | ||
| Q3 25 | 0.52× | 1.01× | ||
| Q2 25 | 0.77× | 1.00× | ||
| Q1 25 | 0.73× | 0.99× | ||
| Q4 24 | 0.75× | 0.97× | ||
| Q3 24 | — | 0.96× | ||
| Q2 24 | — | 0.95× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
RLJ
| Room revenue | $275.3M | 81% |
| Food and beverage revenue | $39.7M | 12% |
| Other revenue | $25.0M | 7% |
